From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Related Posts
Josep Tabernero: 1 of the 11 Catalonia-based candidates for DIARIO MEDICO´s Top 25 ambassadors of biomedicine and healthcare in Spain – VOTING NOW OPEN
In celebration of its 25th Anniversary, DIARIO MEDICO – one of Spain´s leading medical periodicals, has just opened a poll…
04 Jul 2017
The passing of one of the greatest supporters of biomedical research and healthcare across Catalonia: Dr. Pere Mir
It is with deep regret and sadness that we write to report the passing of one of the greatest supporters…
13 Mar 2017
Translational cancer research for tomorrow´s targeted therapy: the barometer of VHIO success
In a joint ecancermedicalscience interview filmed at ASCO 2011 in Chicago, José Baselga and Josep Tabernero describe the early beginnings…
04 Jul 2011
Gastrointestinal Cancers Symposium 2015: findings from a phase III study indicate a possible new treatment strategy for patients with advanced colorectal cancer
Results from an international phase III study of patients with advanced colorectal cancer, a disease which is especially difficult to…
16 Jan 2015
VHIO´s Javier Cortes comments: Two Anti-HER2 Antibodies Better than One
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
Co-author Javier Cortés, Principle Investigator of VHIO´s Breast Cancer and Melanoma Group, describes the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) randomized trial, the importance and implications of the findings, as well as signposts future directions.
29 Dec 2011
Studies Report New Findings on Treatment Options for Mesothelioma
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target Is PD-L1 a…
30 Sep 2014
Nature Reviews Cancer Perspectives/Opinion article: an exploration of the precise and predictive powers of PDX models – now and in the future
In a recent Perspectives/Opinion article* published online in Nature Reviews Cancer, members of the EurOPDX Consortium, including VHIO´s Joaquín Arribas,…
16 Feb 2017
ecancerTV/SABCS 2015 interview: Javier Cortes discusses efficacy and gene expression results from eribulin neoadjuvant study
At the recent annual San Antonio Breast Cancer Symposium (SABCS), 8 – 12 December, San Antonio, USA, the ecancerTV team…
04 Jan 2016
Novel anti-cancer agent proves effective against advanced ALK-positive non-small cell lung cancer (NSCLC)
Published today in The New England Journal of Medicine, a multi-center phase I clinical study conducted across 11 countries, co-authored by Enriqueta Felip, Principal Investigator of VHIO´s Thoracic Tumors Group, represents an important step forward in the treatment of patients with ALK-rearranged lung cancer.
27 Mar 2014
2015 RTICC Prize for Collaborative Research in Oncology awarded to VHIO´s Growth Factors Group
An initiative aimed at promoting collaborative research of excellence in oncology and, more specifically, recognizing the contributions of young cancer…
22 Oct 2015
ecancer catches up with VHIO´s Paolo Nuciforo during the 2015 WIN Symposium
During last month´s WIN – Worldwide Innovative Networking in personalized cancer medicine, Symposium, June 29 – 30, Paris, France, ecancer…
07 Jul 2015
VHIO´s Enriqueta Felip: recipient of the recently launched ESMO Women for Oncology Award
Source: The European Society for Medical Oncology (ESMO) Lugano, Switzerland, 27 August 2015 — The European Society for Medical Oncology…
01 Sep 2015
04 February: THE international day against cancer
World Cancer Day is the singular initiative under which the UICC (Union for International Cancer Control), its members, partners, supporters…
29 Jan 2014
A new treatment, fresh hope and future horizons for metastatic breast cancer patients in Spain
Officially announced today, Halaven ® (Eribulin) has received reimbursement approval from the Spanish Directorate General of Pharmacy and Health Products,…
05 Sep 2013
Launched today by Roche: a 21-strong academic powerhouse set to progress discovery in cancer immunotherapy
Celebrated today at a kick-off meeting in Washington DC, USA, the pharmaceutical company Roche, has just announced the creation of…
15 Nov 2016
